Novo Nordisk has stopped selling Rybelsus, its oral semaglutide tablet, in the United States and is now calling semaglutide pills by the Ozempic brand name instead. This change makes the pill version match the name of the popular injection form.

• •Novo Nordisk has retired the Rybelsus brand in the US
• •Oral semaglutide will now be marketed under the Ozempic name
• •Move unifies pill and injection under a single brand

Novo Nordisk rebranded its oral semaglutide pill Rybelsus under the Ozempic name, aligning the product with its popular injection brand. Amgen reduced the size of its drug development pipeline.

• •Novo Nordisk rebranded oral semaglutide Rybelsus under the Ozempic name
• •Rebrand aligns the pill with Novo's injection franchise
• •Amgen reduced the size of its drug development pipeline

GoodRx, a prescription discount service, now offers Rybelsus (the oral tablet form of semaglutide, the active ingredient in Ozempic) to patients with type 2 diabetes. The move expands GoodRx's existing GLP-1 product lineup to include an oral option alongside injectable versions.

• •GoodRx now offers Rybelsus, the oral tablet form of semaglutide, for type 2 diabetes patients
• •Move expands GoodRx's existing GLP-1 lineup to include an oral option alongside injectables